Angiographic quantification of angiogenesis

Matthew J. Gounis, Baruch B. Lieber, Keith A Webster, Bernard J. Wasserlauf, Howard M. Prentice, Ajay K. Wakhloo

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Therapeutic angiogenesis is the attempt to increase vascular density by means of an exogenously administered proangiogenic agent and offers a potential treatment for diseases associated with tissue ischemia. Vascular endothelial growth factor (VEGF) expressed by gene therapy has been shown to be a potent stimulator of angiogenesis and to improve the function of ischemic tissues in patients [Isner, 1998]. Unregulated gene therapy is disconcerting since there is no assurance that the treatment will target the ischemic territory. A new regulated adeno-associated viral vector expressing VEGF 163 that is conditionally silenced has been developed by one of the authors (KAW). The transgene expression is regulated by silencing the genes in the absence of the disease and at the same time having strong and local activation in the presence of the disease. The purpose of this work is to establish protocols and techniques to quantify the efficacy of therapeutic angiogenesis. The initial phase of this research involves assessment of angiogenesis using an unregulated, adenoviral vector that is encoded to express VEGF 165. Using the rabbit hind limb ischemia model, angiography was performed on animals that were given the proangiogenic treatment and on a sham group, in which phosphate buffered saline (PBS) was injected. Angiographic contrast intensity curves were obtained, modeled, and the optimized model parameters provided insight into flow characteristics within the targeted vascular bed. In the second phase of the project the conditionally silent vector will be employed using the developed protocols and methods of the first phase to afford comparisons with the previous groups.

Original languageEnglish (US)
Title of host publicationAmerican Society of Mechanical Engineers, Bioengineering Division (Publication) BED
PublisherAmerican Society of Mechanical Engineers (ASME)
Pages295-296
Number of pages2
Volume55
DOIs
StatePublished - 2003
Event2003 ASME International Mechanical Engineering Congress - Washington, DC., United States
Duration: Nov 15 2003Nov 21 2003

Other

Other2003 ASME International Mechanical Engineering Congress
CountryUnited States
CityWashington, DC.
Period11/15/0311/21/03

Fingerprint

Gene therapy
Tissue
Angiography
Animals
Phosphates
Genes
Chemical activation
Intercellular Signaling Peptides and Proteins

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Gounis, M. J., Lieber, B. B., Webster, K. A., Wasserlauf, B. J., Prentice, H. M., & Wakhloo, A. K. (2003). Angiographic quantification of angiogenesis. In American Society of Mechanical Engineers, Bioengineering Division (Publication) BED (Vol. 55, pp. 295-296). American Society of Mechanical Engineers (ASME). https://doi.org/10.1115/IMECE2003-43196

Angiographic quantification of angiogenesis. / Gounis, Matthew J.; Lieber, Baruch B.; Webster, Keith A; Wasserlauf, Bernard J.; Prentice, Howard M.; Wakhloo, Ajay K.

American Society of Mechanical Engineers, Bioengineering Division (Publication) BED. Vol. 55 American Society of Mechanical Engineers (ASME), 2003. p. 295-296.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Gounis, MJ, Lieber, BB, Webster, KA, Wasserlauf, BJ, Prentice, HM & Wakhloo, AK 2003, Angiographic quantification of angiogenesis. in American Society of Mechanical Engineers, Bioengineering Division (Publication) BED. vol. 55, American Society of Mechanical Engineers (ASME), pp. 295-296, 2003 ASME International Mechanical Engineering Congress, Washington, DC., United States, 11/15/03. https://doi.org/10.1115/IMECE2003-43196
Gounis MJ, Lieber BB, Webster KA, Wasserlauf BJ, Prentice HM, Wakhloo AK. Angiographic quantification of angiogenesis. In American Society of Mechanical Engineers, Bioengineering Division (Publication) BED. Vol. 55. American Society of Mechanical Engineers (ASME). 2003. p. 295-296 https://doi.org/10.1115/IMECE2003-43196
Gounis, Matthew J. ; Lieber, Baruch B. ; Webster, Keith A ; Wasserlauf, Bernard J. ; Prentice, Howard M. ; Wakhloo, Ajay K. / Angiographic quantification of angiogenesis. American Society of Mechanical Engineers, Bioengineering Division (Publication) BED. Vol. 55 American Society of Mechanical Engineers (ASME), 2003. pp. 295-296
@inproceedings{8e90b06b8686402090e4da8e57a0f389,
title = "Angiographic quantification of angiogenesis",
abstract = "Therapeutic angiogenesis is the attempt to increase vascular density by means of an exogenously administered proangiogenic agent and offers a potential treatment for diseases associated with tissue ischemia. Vascular endothelial growth factor (VEGF) expressed by gene therapy has been shown to be a potent stimulator of angiogenesis and to improve the function of ischemic tissues in patients [Isner, 1998]. Unregulated gene therapy is disconcerting since there is no assurance that the treatment will target the ischemic territory. A new regulated adeno-associated viral vector expressing VEGF 163 that is conditionally silenced has been developed by one of the authors (KAW). The transgene expression is regulated by silencing the genes in the absence of the disease and at the same time having strong and local activation in the presence of the disease. The purpose of this work is to establish protocols and techniques to quantify the efficacy of therapeutic angiogenesis. The initial phase of this research involves assessment of angiogenesis using an unregulated, adenoviral vector that is encoded to express VEGF 165. Using the rabbit hind limb ischemia model, angiography was performed on animals that were given the proangiogenic treatment and on a sham group, in which phosphate buffered saline (PBS) was injected. Angiographic contrast intensity curves were obtained, modeled, and the optimized model parameters provided insight into flow characteristics within the targeted vascular bed. In the second phase of the project the conditionally silent vector will be employed using the developed protocols and methods of the first phase to afford comparisons with the previous groups.",
author = "Gounis, {Matthew J.} and Lieber, {Baruch B.} and Webster, {Keith A} and Wasserlauf, {Bernard J.} and Prentice, {Howard M.} and Wakhloo, {Ajay K.}",
year = "2003",
doi = "10.1115/IMECE2003-43196",
language = "English (US)",
volume = "55",
pages = "295--296",
booktitle = "American Society of Mechanical Engineers, Bioengineering Division (Publication) BED",
publisher = "American Society of Mechanical Engineers (ASME)",

}

TY - GEN

T1 - Angiographic quantification of angiogenesis

AU - Gounis, Matthew J.

AU - Lieber, Baruch B.

AU - Webster, Keith A

AU - Wasserlauf, Bernard J.

AU - Prentice, Howard M.

AU - Wakhloo, Ajay K.

PY - 2003

Y1 - 2003

N2 - Therapeutic angiogenesis is the attempt to increase vascular density by means of an exogenously administered proangiogenic agent and offers a potential treatment for diseases associated with tissue ischemia. Vascular endothelial growth factor (VEGF) expressed by gene therapy has been shown to be a potent stimulator of angiogenesis and to improve the function of ischemic tissues in patients [Isner, 1998]. Unregulated gene therapy is disconcerting since there is no assurance that the treatment will target the ischemic territory. A new regulated adeno-associated viral vector expressing VEGF 163 that is conditionally silenced has been developed by one of the authors (KAW). The transgene expression is regulated by silencing the genes in the absence of the disease and at the same time having strong and local activation in the presence of the disease. The purpose of this work is to establish protocols and techniques to quantify the efficacy of therapeutic angiogenesis. The initial phase of this research involves assessment of angiogenesis using an unregulated, adenoviral vector that is encoded to express VEGF 165. Using the rabbit hind limb ischemia model, angiography was performed on animals that were given the proangiogenic treatment and on a sham group, in which phosphate buffered saline (PBS) was injected. Angiographic contrast intensity curves were obtained, modeled, and the optimized model parameters provided insight into flow characteristics within the targeted vascular bed. In the second phase of the project the conditionally silent vector will be employed using the developed protocols and methods of the first phase to afford comparisons with the previous groups.

AB - Therapeutic angiogenesis is the attempt to increase vascular density by means of an exogenously administered proangiogenic agent and offers a potential treatment for diseases associated with tissue ischemia. Vascular endothelial growth factor (VEGF) expressed by gene therapy has been shown to be a potent stimulator of angiogenesis and to improve the function of ischemic tissues in patients [Isner, 1998]. Unregulated gene therapy is disconcerting since there is no assurance that the treatment will target the ischemic territory. A new regulated adeno-associated viral vector expressing VEGF 163 that is conditionally silenced has been developed by one of the authors (KAW). The transgene expression is regulated by silencing the genes in the absence of the disease and at the same time having strong and local activation in the presence of the disease. The purpose of this work is to establish protocols and techniques to quantify the efficacy of therapeutic angiogenesis. The initial phase of this research involves assessment of angiogenesis using an unregulated, adenoviral vector that is encoded to express VEGF 165. Using the rabbit hind limb ischemia model, angiography was performed on animals that were given the proangiogenic treatment and on a sham group, in which phosphate buffered saline (PBS) was injected. Angiographic contrast intensity curves were obtained, modeled, and the optimized model parameters provided insight into flow characteristics within the targeted vascular bed. In the second phase of the project the conditionally silent vector will be employed using the developed protocols and methods of the first phase to afford comparisons with the previous groups.

UR - http://www.scopus.com/inward/record.url?scp=1842508240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842508240&partnerID=8YFLogxK

U2 - 10.1115/IMECE2003-43196

DO - 10.1115/IMECE2003-43196

M3 - Conference contribution

VL - 55

SP - 295

EP - 296

BT - American Society of Mechanical Engineers, Bioengineering Division (Publication) BED

PB - American Society of Mechanical Engineers (ASME)

ER -